Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | NSD2 | O96028 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CNR1 | P21554 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9221541 | 0.89 | ACLY (0.40) | LMNANSD2ALDH1A1CNR1TP53 | |
| SCHEMBL3488515 | 0.87 | ACLY (0.52) | NSD2ALDH1A1MAPTCYP19A1USP2 | |
| SCHEMBL3489075 | 0.87 | ALDH1A1 (0.52) | LMNAALDH1A1CNR1CYP19A1 | |
| SCHEMBL9213886 | 0.87 | CYP19A1 (0.51) | NSD2ALDH1A1MAPTCYP19A1HTT | |
| SCHEMBL3488631 | 0.86 | KMT2A (0.52) | LMNAALDH1A1CYP19A1HTTSMN1; SMN2 | |
| SCHEMBL9220530 | 0.85 | PGR (0.44) | LMNANSD2ALDH1A1MAPT | |
| SCHEMBL9210947 | 0.85 | SMN1; SMN2 (0.50) | LMNAALDH1A1MAPTHTTTSHR | |
| SCHEMBL3490453 | 0.84 | POLB (0.51) | LMNAALDH1A1TP53MAPTHTT | |
| SCHEMBL3489110 | 0.84 | ALDH1A1 (0.44) | LMNAALDH1A1TP53CYP19A1 | |
| SCHEMBL3489635 | 0.83 | CYP19A1 (0.43) | LMNAALDH1A1MAPTCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035866-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035866-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OPRD1, HTR6, HTR1D | LMNA 4446/4885NSD2 3705/4885ALDH1A1 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.